Business Wire

Elliott Welcomes Bezeq’s Governance Overhaul

Del

Elliott Advisors (UK) Limited (“Elliott”), which advises funds that collectively comprise one of the largest shareholders in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), today sent a letter to Bezeq’s newly appointed Board Chairman Shlomo Rodav, sharing its views on Bezeq’s governance transformation and proposing that the Company consider a share buyback programme.

Elliott’s letter highlights the poor corporate governance that persisted at the Company over a number of years, leading to an Israel Securities Authority investigation, and a number of board members and executives being placed under house arrest and barred from the Company. Culminating in last week’s election of Chairman Rodav, the Company’s refreshed Board brings much needed independence and experience.

Now that the long overdue governance overhaul has been achieved, Elliott recommends that the following action items be undertaken without further delay: (i) appoint a new CEO; (ii) rebuild a constructive regulatory dialogue; (iii) develop a coherent new strategy for the business balancing growth with efficiency gains; (iv) review shareholder distribution policy, immediately seeking authorization to buy back shares and consider implementing a buyback programme when appropriate; and (v) conduct robust domestic and international engagement with shareholders, clearly communicating a plan to create value.

Elliott’s letter is latest in a series of communications with the Company this past year, and follows up on recent conversations with Chairman Rodav and other members of Bezeq’s board.

Full text of the letter can be read below.

About Elliott

Elliott Management Corporation manages two multi-strategy funds which combined have approximately $35 billion of assets under management. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.

***

May 17, 2018

 

Via Email

Mr Shlomo Rodav
Chairman
Bezeq The Israel Telecommunication Corporation Ltd.
The Triangular Tower
3 Azrieli Center
Tel Aviv 61620, Israel
Attention: Shlomo Rodav, Chairman of the Board of Directors
 

Dear Mr Rodav,

We appreciate our recent phone conversations about the future of Bezeq The Israel Telecommunication Corporation Ltd. (“Bezeq” or the “Company”). As the funds we advise are (collectively) one of Bezeq’s largest shareholders, we want to reiterate our optimism at your appointment as Chairman of the Board of Directors. Bezeq has undergone a major governance overhaul in recent months, providing a foundation for you and a new leadership team to drive shareholder value. We are writing today to offer our views on the importance of these governance changes and to propose that the Company consider supporting shareholder value by implementing a share buyback programme. Shares could be acquired from the market or, if feasible, from the Eurocom Group. To facilitate this, we believe Bezeq should immediately seek authorisation to acquire up to 10% of its shares, which would allow the Company to opportunistically buy back shares when appropriate.

Governance Transformation

Over the past year, Bezeq has operated under extreme uncertainty, with a lack of clear leadership and strategic direction, poor investor communications, and a stalled regulatory dialogue. These interrelated problems stemmed from the poor corporate governance that persisted at the Company over a number of years. This led to an Israel Securities Authority investigation and a number of board members and executives being placed under house arrest and barred from the Company. This has all occurred at a time of accelerating competition and change in the Israeli telecom market.

We are encouraged by the progress made in normalising Bezeq’s corporate governance. Following the AGM, and your subsequent election as Chairman, we believe that Bezeq now has a much improved Board of Directors. In contrast to when we first began our engagement with Bezeq, the Company’s refreshed Board is independent and brings experience of the Company itself and the Israeli telecom market as well as the management and governance of large companies. Having spoken with you and a number of your fellow directors, we are encouraged by your commitment to work collectively for the benefit of Bezeq and all its stakeholders without bias toward any shareholder who nominated you.

Valuation and Share Buyback

We continue to believe that Bezeq is fundamentally a well-positioned and resilient business, where—following a sustained period of poor governance and management—a new leadership team can drive performance improvements and rebuild shareholder value. Bezeq’s shares, in our view, are currently trading well below their fundamental value on multiple dimensions. Bezeq has one of the highest equity free cash flow yields (~11%) of any incumbent telecom company in the EMEA region. This yield is based on the 2018 earnings and cash flow, which we believe is likely to be a low point, reflecting the pricing initiative taken at Yes earlier this year, but none of the anticipated cost savings from combining Yes and Bezeq International. This also neglects the likely growth and efficiency initiatives that may be pursued by a new team. The shares trade well below the discounted cash flow valuations of every sell-side analyst covering the stock.

This discount to fundamentals implies that it would be accretive for Bezeq to buy back its own shares. This could be funded by the ~ILS 500m proceeds from the Sakia real estate disposal and by modest incremental borrowings, appropriately sized to avoid impacting Bezeq’s credit rating or significantly affecting borrowing costs.

Next Steps

Now that the governance problems at Bezeq have been resolved and a new Board of Directors is in place, it is imperative that the following steps be taken without further delay:

(i) Appoint a new CEO;

(ii) Rebuild a constructive regulatory dialogue;

(iii) Develop a coherent new strategy for the business balancing growth with efficiency gains;

(iv) Review shareholder distribution policy including immediately seeking authorization to buy back shares and consider implementing a buyback programme when appropriate; and

(v) Conduct robust domestic and international engagement with shareholders, clearly communicating a plan to create value.

Bezeq’s new Board should be well positioned to effectively govern the company in the interest of all shareholders. We appreciate your leadership in this new phase for Bezeq, and look forward to our continued dialogue.

Yours sincerely,

Elliott Advisors (UK) Limited

Contact information

Media
London
Sarah Rajani CFA
Elliott Advisors (UK) Limited
+44 (0) 20 3009 1475
srajani@elliottadvisors.co.uk
or
Tel Aviv
Eyal Arad
+972 (54) 669-9996
eyal@aradcomm.co.il

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 12:00Pressemelding

Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior

NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 12:00Pressemelding

NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip

Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 11:27Pressemelding

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 11:00Pressemelding

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 10:11Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 10:06Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo